VX-670
Vertex Pharmaceuticals' investigational cyclic peptide-oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), using Entrada Therapeutics' Endosomal Escape Vehicle (EEV) cyclic peptide to deliver an antisense oligonucleotide targeting DMPK mRNA.
What is VX-670?
VX-670 is Vertex Pharmaceuticals' investigational peptide-oligonucleotide conjugate (POC) for myotonic dystrophy type 1 (DM1) — a CTG-repeat-expansion disease in the DMPK gene that causes progressive muscle weakness, myotonia, cardiac conduction abnormalities, and multisystem involvement. The molecule combines an antisense oligonucleotide targeting DMPK mRNA with Entrada Therapeutics' Endosomal Escape Vehicle (EEV) — a proprietary cyclic peptide platform designed to deliver oligonucleotide cargo across cell membranes to the cytoplasm where DMPK mRNA can be degraded. Vertex acquired Entrada's DM1 program in 2024, with VX-670 entering Phase 1 in 2024–2025. As of mid-2026, the program represents one of the most advanced clinical efforts to deliver disease-modifying therapy to DM1, a condition with no approved disease-modifying treatments.
What VX-670 Is Investigated For
VX-670 is the most clinically advanced peptide-mediated approach to myotonic dystrophy type 1 (DM1) — a CTG-repeat-expansion disorder of the DMPK gene affecting roughly 1 in 8,000 globally that produces progressive muscle weakness, myotonia, and multisystem complications. The strongest evidence is preclinical: Entrada's EEV cyclic peptide platform has demonstrated efficient oligonucleotide delivery to muscle tissue in animal models, with reduction in toxic CUG-repeat-containing DMPK mRNA aggregates and rescue of downstream splicing defects. Phase 1 clinical data is anticipated to read out across 2025–2026; as of mid-2026, the program is in active dose-escalation. The honest caveats: VX-670 is Phase 1 stage, the EEV cyclic peptide delivery platform is novel and its long-term safety and durability are not established, and previous oligonucleotide approaches to DM1 (PepGen's PGN-EDODM1 was discontinued) have faced significant translation challenges. Vertex's acquisition signals confidence in the program but does not guarantee clinical success.
History & Discovery
The DM1 disease mechanism (CTG-repeat expansion in DMPK 3' UTR producing toxic CUG-repeat RNA) was established in the 1990s, and antisense oligonucleotide-based therapy targeting DMPK has been a therapeutic strategy since then. Multiple oligonucleotide approaches have been pursued (BIIB100 / IONIS-DMPK-2.5Rx; PepGen's PGN-EDODM1; Avidity's AOC; Vertex/Entrada's VX-670), with varying delivery strategies attempting to overcome the muscle-delivery and endosomal escape problem. Entrada Therapeutics was founded around the EEV cyclic peptide platform with multiple oligonucleotide payloads in development. Vertex Pharmaceuticals acquired Entrada's DM1 program in 2024 as part of Vertex's broader push into peripheral myopathies and rare diseases beyond cystic fibrosis (where Vertex has dominated for decades). VX-670 entered Phase 1 in 2024–2025 with dose-escalation across DM1 patients. As of mid-2026, the program is in active development with anticipated initial readouts at oncology and neuromuscular conferences across 2025–2026. The DM1 therapeutic landscape is highly contested, with Avidity's del-zota and other peptide-oligonucleotide programs pursuing similar mechanistic strategies. PepGen's PGN-EDODM1 program was discontinued in 2024 after Phase 1 results showed lower-than-expected exon skipping. The competitive dynamics among VX-670, Avidity's program, and Ionis/Biogen's BIIB100 will play out across 2026–2028.
How It Works
Myotonic dystrophy type 1 is caused by a defective version of a gene called DMPK that produces toxic RNA, which gums up the muscles and causes weakness. VX-670 uses a special cyclic peptide as a 'delivery truck' to carry an antisense drug into muscle cells, where the drug breaks down the toxic RNA. The peptide is the delivery vehicle; the antisense oligonucleotide is the payload that does the therapeutic work.
VX-670 consists of two components conjugated together: (1) Entrada's Endosomal Escape Vehicle (EEV) — a proprietary cyclic peptide engineered to be taken up by cells via endocytosis and then to mediate escape from endosomes into the cytoplasm where the cargo can act; (2) an antisense oligonucleotide that hybridizes to the toxic CUG-repeat-containing DMPK mRNA, leading to RNase H-mediated cleavage and reduction in nuclear foci. The critical biological problem for any oligonucleotide therapy is that the molecule must reach the relevant tissue (muscle, in this case) and then escape the endosome into the cytoplasm where it can act. Naked oligonucleotides reach tissue poorly and remain trapped in endosomes; lipid nanoparticles (used in mRNA vaccines) primarily reach the liver. The EEV cyclic peptide is designed to address both delivery and endosomal escape in a single conjugate. Preclinical work demonstrated efficient muscle uptake and reduction of DMPK mRNA foci in mouse models. The translational question for VX-670 is whether the EEV platform delivers sufficient oligonucleotide to human skeletal and cardiac muscle to produce splicing-correction levels comparable to the preclinical results. Phase 1 biomarker readouts (e.g., MBNL-regulated splicing correction in muscle biopsy) will be informative.
Evidence Snapshot
Human Clinical Evidence
Phase 1 dose-escalation in DM1 patients ongoing as of 2025–2026. No mature published clinical efficacy data yet.
Animal / Preclinical
Strong. EEV-delivered oligonucleotides have demonstrated DMPK mRNA reduction and splicing correction in DM1 mouse models.
Mechanistic Rationale
Strong. The antisense oligonucleotide strategy for DM1 is mechanistically validated; the EEV cyclic peptide delivery is novel but rationally designed.
Research Gaps & Open Questions
What the current literature has not yet settled about VX-670:
- 01Phase 1 efficacy and target engagement data — pending publication.
- 02EEV cyclic peptide platform safety over years — not yet characterized.
- 03Long-term durability of mRNA reduction in muscle — DMPK mRNA turnover and re-accumulation patterns unknown.
- 04Cardiac DM1 effects — DM1 produces cardiac conduction abnormalities; whether VX-670 reaches cardiac muscle adequately is an open question.
- 05CNS effects of DM1 — DM1 has cognitive and behavioral features; whether peripheral oligonucleotide therapy modifies these is unknown.
- 06Comparison with Avidity's del-zota and other competing DM1 oligonucleotide approaches.
Forms & Administration
Intravenous or subcutaneous administration in Phase 1 protocols. Not commercially available.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Phase 1 dose-escalation. Specific dosing pending publication.
Frequency
Likely periodic (weekly to monthly) infusion or subcutaneous administration pending pharmacokinetic data.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Chronic indefinite for a disease-modifying approach.
Protocol Notes
VX-670 is not available outside clinical trials. Patients with DM1 should discuss clinical trial enrollment options with their neuromuscular medicine specialist.
VX-670 is investigational and Phase 1 stage. DM1 management requires neuromuscular medicine specialty care.
Timeline of Effects
Onset
To be characterized.
Peak Effect
To be characterized.
After Discontinuation
Antisense oligonucleotide-mediated mRNA reduction typically dissipates over weeks following discontinuation as new mRNA is produced.
Common Questions
Who VX-670 Is NOT For
- •Use outside DM1 — VX-670 is highly specific to the DMPK-targeting mechanism.
- •Pregnancy and breastfeeding — limited safety data; not appropriate.
- •Pediatric use outside trial protocols — Phase 1 in adults; pediatric program separate.
- •Active malignancy — long-term oligonucleotide and EEV exposure has theoretical considerations.
- •Known hypersensitivity to peptide therapeutics.
Drug & Supplement Interactions
Specific drug interactions for VX-670 will be characterized in Phase 1/2 development. DM1 patients are often on multiple medications for cardiac, muscle, and metabolic symptoms; coordination through neuromuscular medicine specialty care is essential.
Safety Profile
Common Side Effects
Cautions
- • Investigational — Phase 1 stage
- • Long-term safety of EEV cyclic peptide delivery platform not established
- • Pediatric, pregnancy, lactation use not characterized
What We Don't Know
Most parameters are unknowns at this development stage — Phase 1 will characterize pharmacokinetics, biodistribution, target engagement, and initial safety signals.
Legal Status
United States
Investigational — not FDA-approved. Phase 1 in DM1 patients.
International
Investigational across major regulators.
Sports & Competition
Not relevant — DM1 indication. Therapeutic Use Exemption applicable for any DM1 patient who is a competitive athlete.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
VX-670 cures myotonic dystrophy.
Reality
DM1 is caused by an underlying genetic mutation (CTG expansion in DMPK). Antisense oligonucleotide therapy reduces the toxic mRNA but does not correct the underlying genetic lesion. Treatment would be chronic and indefinite if approved, and complete normalization of all DM1 features (cardiac, cognitive, muscle, multisystem) is not expected.
Myth
EEV cyclic peptide delivery solves all oligonucleotide therapy problems.
Reality
EEV addresses two specific challenges (tissue delivery and endosomal escape) but does not eliminate all oligonucleotide therapy hurdles — durability, immunogenicity, manufacturing, cost, and tissue-distribution heterogeneity all remain.
Quick Facts
- Class
- Cyclic Peptide-Oligonucleotide Conjugate
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- May 2026
- Citations
- 0PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.